Aligos Therapeutics (Aligos Therapeutics) 5-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aligos Therapeutics 5-Year Dividend Growth Rate?

Aligos Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Aligos Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Aligos Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Aligos Therapeutics's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Aligos Therapeutics's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aligos Therapeutics's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's 5-Year Dividend Growth Rate falls into.

Aligos Therapeutics 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Aligos Therapeutics (NAS:ALGS) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Aligos Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.22
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Aligos Therapeutics's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aligos Therapeutics (Aligos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aligos Therapeutics Inc (NAS:ALGS) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

5WK:Germany 5WK:Germany

Address

One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080

Website

https://www.aligos.com

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Executives

Roche Finance Ltd	10 percent owner	C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd	10 percent owner	ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Carole Nuechterlein	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Matthew W. Mcclure	officer: Chief Medical Officer	C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Paul Scopa	director	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Thomas Woiwode	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Surplus Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Julian A. Symons	officer: See Remarks	C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Leonid Beigelman	director, officer: President	C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lucinda Y. Quan	officer: See Remarks	C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lawrence Blatt	director, officer: Chief Executive Officer